| answer text |
<p>During the last five years, NHS England commissioned a health technology assessment
to review the clinical evidence for Kalydeco (Ivacaftor) and decided at the time that
it would support its use to treat one gene mutation. Subsequently it has broadened
use for other gene mutations following further evidence reviews.</p><p> </p><p>For
commissioned drugs such as Kalydeco (Ivacaftor) for named mutations, prescribing decisions
are made by multidisciplinary teams in hospitals commissioned by NHS England to provide
specialised services for adults and children with cystic fibrosis.</p><p> </p><p>NHS
England is investing significant resources into the provision of Kalydeco which works
directly on the genes causing cystic fibrosis and in medicines that reduce the impact
of the disease.</p><p> </p><p>NHS England and the Cystic Fibrosis Trust jointly collect
outcomes data through the Cystic Fibrosis Registry to inform better management of
the disease.</p><p> </p><p>Information about specialised National Health Service commissioning
is available at the following link:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a01/"
target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a01/</a></p>
|
|
